How the Grp94 helper protein folds insulin-like growth factors

Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors

NIH-funded research Brandeis University · NIH-11329533

This research looks at how a helper protein called Grp94 works with another chaperone to correctly shape insulin-like growth factors, which matters for people with cancers and other IGF-related conditions.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionBrandeis University NIH-funded
Lab location1 site (Waltham, United States)
Project IDNIH-11329533 on NIH RePORTER

What this research studies

Researchers will examine how Grp94 and the chaperone BiP interact to decide whether insulin-like growth factors are folded for secretion or kept for degradation. They will use purified proteins, structural and biochemical experiments, and cell-based assays to watch docking, conformational changes, and client transfer between BiP and Grp94. The team aims to identify the conditions that favor transfer of IGF clients onto Grp94 and to determine what folding benefit that transfer provides. The work focuses on molecular mechanisms that could point to targets for future therapies.

Who could benefit from this research

Good fit: People with cancers or other conditions linked to abnormal IGF signaling, or those interested in contributing tissue or biospecimens for IGF biology research, would be most relevant.

Not a fit: Patients without IGF-related conditions or those seeking immediate clinical treatments are unlikely to benefit directly from this basic laboratory research.

Why it matters

Potential benefit: If successful, the findings could reveal new molecular steps to target that might help control IGF-related pathways in cancer or growth disorders.

How similar studies have performed: Previous laboratory studies have shown that chaperones like Grp94 and BiP guide protein folding, but translating that knowledge into therapies remains largely untested.

Where this research is happening

Waltham, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer AgentsCancer Drug
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.